AXIM Biotech (AXIM)

In response to the growing opioid epidemic, AXIM® Biotechnologies, Inc. (OTC:AXIM) CEO Dr. George E. Anastassov was appointed to the American Pain Association’s (APA’s) Board of Advisors. Dr. Anastassov’s extensive career experience in cannabis-based treatment research is expected to provide a helpful perspective on treatment for the millions of opioid addiction cases around the world. Over the past 15 years, there have been more than 50,000 fatalities related to drug overdose in the United States alone.

Prescription drug abuse is the most rapidly growing drug addiction issue in the United States. Nearly one-third of Americans ages 12 and over who were surveyed in a 2009 National Survey on Drug Use and Health study reported that they first began using prescription drugs for non-medical purposes. More than 70 percent of Americans who abused prescription drugs received them from family members or friends who had a prescription.

The Opioid Epidemic

The opioid epidemic is a severe problem worldwide, and in the United States alone it claims more than 40 lives each day. Addiction is the leading health crisis in America, exceeding gun and traffic accidents in terms of annual fatalities. According to the Centers for Disease Control and Prevention (CDC), conservative estimates hold that half of all opioid deaths each year involve a legally-obtained prescription. One of the most tragic aspects of opioid addiction is that many people first become addicted while using legal opioids as a treatment for a medical condition such as back pain.

One Journal of the American Medical Association (JAMA) internal medicine study in 2014 found that states in which cannabis is a viable and legal treatment option see a 25 percent reduction in the number of deaths caused by prescription painkiller abuse.

AXIM Biotech has developed a powerful new treatment option with a variety of promising treatment indications. MedChew Rx is set for registration by the EMA and the FDA by the end of 2017. MedChew Rx is expected to change medication delivery for patients with many different conditions around the world. The product has an estimated market potential of $4.8 billion as a treatment option for chronic pain and spasticity, which are common symptoms of multiple sclerosis.

The APA and Dr. Anastassov

In addition to the innovative medical technologies being created by Dr. Anastassov and AXIM Biotech, the doctor’s partnership with the APA holds promise for new solutions in the treatment of chronic pain. Chronic pain and other chronic conditions are often treated with medications that are not meant to be used on a long-term basis, such as opioids. Cannabis-based treatment options do not present the same risk of chemical addiction, making them more viable for long-term symptom relief. MedChew Rx is one example of AXIM Biotech’s powerful medical formulations that could be used to treat the symptoms of various conditions without the negative side effects of other prescription drugs. Because MedChew Rx does not have any psychotropic effects, it is a safe and effective treatment for many patients and does not lead to an altered state of consciousness.

At the present time, some lawmakers do not believe that medical marijuana is an appropriate medical treatment. Marijuana is currently a Schedule I drug and medical marijuana is banned in many states, despite promising studies that suggest its effectiveness as a non-addictive treatment option.

Many myths surrounding the use of medical marijuana and its effects have led to misunderstandings even within the medical community. Dr. Anastassov’s addition with the APA’s Board of Advisors is a promising step towards improving education about the benefits of medical marijuana products as a viable treatment option. With more education and awareness, patients around the world can experience easier access to these life-changing products. Medical marijuana has been scientifically proven as an effective way to combat the opioid epidemic, which puts AXIM Biotech and Dr. Anastassov at the forefront of the movement to save lives and stop prescription drug addiction.

About the Author

Stuart Smith is the CEO and Founder of is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about and their services, please visit